Testing abdominal chemo plus standard chemo for stomach cancer spread
Part of Cancer, Digestive system clinical trials.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is a type called adenocarcinoma of the stomach or where the stomach meets the food pipe, and it has spread to the lining of your abdomen (confirmed by tests or surgery).
- You have already received 3 to 6 months of first chemotherapy treatment and have not had major side effects from it.
- You do not have cancer spread to other organs (like liver or lungs) except possibly the ovaries, and you have no blockage in your small or large bowel.
- You are well enough to have a minor surgery (laparoscopy) to place a port in your abdomen for the extra chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
This trial tests a new treatment combination for locally advanced stomach cancer. First, you would receive a heated chemotherapy wash inside your abdomen (HIPEC). Then you would get the immunotherapy drug serplulimab plus standard chemotherapy (SOX or XELOX) before surgery, to shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
This trial looks at a way to give chemotherapy into the abdomen (through a small tube during laparoscopy) for certain stomach cancers. It aims to see whether this approach improves cancer control and surgical outcomes for people whose tumors can potentially be removed.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.